VRTX discontinues VX-264 T1D treatment due to low efficacy; VX-880 remains and has been renamed, Zimislecel: https://www.businesswire.com/news/home/20250328622122/en/Vertex-Announces-Program-Updates-for-Type-1-Diabetes-Portfolio See #msg-172224254 for background info.